CA2056421C - Agent against autoimmune diseases - Google Patents

Agent against autoimmune diseases Download PDF

Info

Publication number
CA2056421C
CA2056421C CA002056421A CA2056421A CA2056421C CA 2056421 C CA2056421 C CA 2056421C CA 002056421 A CA002056421 A CA 002056421A CA 2056421 A CA2056421 A CA 2056421A CA 2056421 C CA2056421 C CA 2056421C
Authority
CA
Canada
Prior art keywords
alkyl
carbon atoms
cells
animals
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002056421A
Other languages
English (en)
French (fr)
Other versions
CA2056421A1 (en
Inventor
Manuel Modolell
Gerhard Munder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Publication of CA2056421A1 publication Critical patent/CA2056421A1/en
Application granted granted Critical
Publication of CA2056421C publication Critical patent/CA2056421C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA002056421A 1989-06-02 1990-05-31 Agent against autoimmune diseases Expired - Fee Related CA2056421C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE3918082A DE3918082A1 (de) 1989-06-02 1989-06-02 Mittel gegen autoimmunerkrankungen
DEP3918082.4 1989-06-02
PCT/EP1990/000870 WO1990014829A1 (de) 1989-06-02 1990-05-31 Lysolecithinderivate zur behandlung von autoimmunerkrankungen

Publications (2)

Publication Number Publication Date
CA2056421A1 CA2056421A1 (en) 1990-12-03
CA2056421C true CA2056421C (en) 2000-10-10

Family

ID=6381972

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002056421A Expired - Fee Related CA2056421C (en) 1989-06-02 1990-05-31 Agent against autoimmune diseases

Country Status (14)

Country Link
US (1) US5266564A (OSRAM)
EP (1) EP0474712B1 (OSRAM)
JP (1) JP2977894B2 (OSRAM)
AT (1) ATE94757T1 (OSRAM)
AU (1) AU5670690A (OSRAM)
CA (1) CA2056421C (OSRAM)
CS (1) CS276439B6 (OSRAM)
DE (2) DE3918082A1 (OSRAM)
DK (1) DK0474712T3 (OSRAM)
ES (1) ES2060173T3 (OSRAM)
GR (1) GR1001195B (OSRAM)
IE (1) IE64039B1 (OSRAM)
WO (1) WO1990014829A1 (OSRAM)
ZA (1) ZA904196B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3941009A1 (de) * 1989-12-12 1991-06-13 Medmark Pharma Gmbh Eliminierung von aktivierten lymphozyten
DE122004000004I1 (de) * 1996-02-09 2004-08-12 Abott Biotechnology Ltd Humane Antikörper welche an Humanen TNFalpha binden.
CA2356736A1 (en) * 1998-12-21 2000-06-29 Inkeysa. S.A. Use of etherlysophospholipids as antiinflammatory agents
SE9902155L (sv) * 1999-06-09 2000-12-10 Bjoern Rydevik Serum antibodies
JP2002228764A (ja) * 2001-02-02 2002-08-14 Fuji Photo Film Co Ltd 透光性シート体検出装置
CN101610758A (zh) * 2006-11-10 2009-12-23 阿尔法普托斯有限公司 含有三取代甘油化合物的口服剂型
US8324188B2 (en) 2006-11-10 2012-12-04 Vladimir Khazak Combinations of ET-18-O-CH3and anti-cancer agents for the treatment of cancer
ES2391659T3 (es) * 2006-11-10 2012-11-28 Radioprotect Alphaptose Ug(Haftungsbeschränkt) & Co. Kg Uso de compuestos de glicerol trisustituido para el tratamiento de lesiones por radiación
EP2120873B1 (en) * 2006-12-20 2012-06-27 Alphaptose Gmbh Topical dosage form comprising tri-substituted glycerol compounds
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
AU2008231570C1 (en) 2007-03-28 2014-11-27 Aker Biomarine Human Ingredients As Bioeffective krill oil compositions
US20100226977A1 (en) * 2007-08-29 2010-09-09 Aker Biomarine Asa Low viscosity phospholipid compositions
CN101827529B (zh) * 2007-08-29 2014-01-15 阿克海洋生物股份公司 制备磷虾粉的方法
US8372812B2 (en) * 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
WO2013156630A1 (en) 2012-04-20 2013-10-24 Alphaptose Gmbh S-enantiomer of a tri-substituted glycerol compound
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
PL3256003T5 (pl) 2015-02-11 2025-11-17 Aker Biomarine Human Ingredients As Sposoby ekstrakcji lipidów
NZ735362A (en) 2015-02-11 2019-01-25 Aker Biomarine Antarctic As Lipid compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2009342C3 (de) * 1970-02-27 1980-12-18 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen Verwendung von Glycerin-alkyläther-(l)-phosphorsäure-(3)-monocholinestern
DE2009343C3 (de) * 1970-02-27 1980-10-23 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen Verwendung von Lysolecithinen als immunologische Adjuvantien
DE2619686C2 (de) * 1976-05-04 1986-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Verwendung eines Lysolecithins zur Tumorbehandlung
CH670763A5 (OSRAM) * 1985-08-02 1989-07-14 Seuref Ag
DE3530767A1 (de) * 1985-08-28 1987-03-12 Max Planck Gesellschaft Mittel gegen multiple sklerose

Also Published As

Publication number Publication date
CA2056421A1 (en) 1990-12-03
US5266564A (en) 1993-11-30
JP2977894B2 (ja) 1999-11-15
DE3918082C2 (OSRAM) 1992-02-06
JPH04507096A (ja) 1992-12-10
CS276439B6 (en) 1992-05-13
DE59002863D1 (de) 1993-10-28
WO1990014829A1 (de) 1990-12-13
IE901987L (en) 1990-12-02
ATE94757T1 (de) 1993-10-15
EP0474712A1 (de) 1992-03-18
GR900100406A (en) 1991-11-15
AU5670690A (en) 1991-01-07
ZA904196B (en) 1991-03-27
GR1001195B (el) 1993-06-07
ES2060173T3 (es) 1994-11-16
IE64039B1 (en) 1995-06-28
DK0474712T3 (da) 1993-11-29
CS268990A3 (en) 1992-01-15
EP0474712B1 (de) 1993-09-22
DE3918082A1 (de) 1991-01-24

Similar Documents

Publication Publication Date Title
CA2056421C (en) Agent against autoimmune diseases
AU693232B2 (en) Treatment of autoimmune diseases by oral administration of autoantigens
EP0359783B1 (en) Treatment of autoimmune diseases by oral administration of autoantigens
Gewurz Biology of C-reactive protein and the acute phase response
Mahley et al. Altered metabolism (in vivo and in vitro) of plasma lipoproteins after selective chemical modification of lysine residues of the apoproteins
US5869093A (en) Treatment of immune diseases by oral administration of autoantigens
US4634590A (en) Cell membrane proteins, compositions containing them and procedure for their preparation
US5869054A (en) Treatment of multiple sclerosis by oral administration of autoantigens
Bito Inflammatory effects of endotoxin-like contaminants in commonly used protein preparations
US20050208061A1 (en) Treatment of autoimmune diseases by oral administration of autoantigens
US5389530A (en) Methods for the production of antibodies and induction of immune responses to tumor-associated ganagliosides by immunization with gangloiside lactones
US3752886A (en) Lysolecithins as immunologic adjuvants
van't Hooft et al. Metabolism of apolipoprotein E in plasma high density lipoproteins from normal and cholesterol-fed rats.
AU665764B2 (en) Methods and compositions for the prevention, diagnosis, and treatment of inflammatory serosal disease and related conditions
JPWO2002092630A1 (ja) 高密度リポ蛋白質反応性ペプチド
Ozato et al. Studies on Lymphocyte-Mediated Cytolysis: XII. Hapten Transferred to Cell Surfaces by Interaction with Liposomes Is Recognized by Antibody But Not by Hapten-Specific H-2 Restricted Cytotoxic T Cells
FI104179B (fi) Menetelmä terapeuttisesti käyttökelpoisen polypeptidin valmistamiseksi
Masala et al. Mucus antibodies in pulmonary tuberculosis and chronic obstructive lung disease
Willenborg et al. Liposomes containing myelin basic protein (BP) suppress but do not induce allergic encephalomyelitis in Lewis rats
Buchta Structure-function studies of the acute phase response protein: C-reactive protein
Sarlo Some biological properties of the mouse acute phase reactant serum amyloid p-component

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed